Medicenna Therapeutics Corp

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada.

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patient MDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage of tumor size following failure with check-point inhibitor therapies MDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the dose escalation cohorts Medicenna believes that these data reaffirm the differentiated and promising therapeutic activity, safety, PD and PK profile of the ‘beta-enhanced not-alpha' albumin-fused IL-2 superkine in patients with advanced solid tumors who have failed current standard of care TORONTO and HOUSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that new clinical data from the Phase 1 monotherapy dose escalation/evaluation portion of the Phase 1/2 ABILITY-1 (A Beta-only IL-2 ImmunoTherapY) study evaluating MDNA11, the only long-acting, ‘beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist in clinical development, in patients with advanced solid tumors, were presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in San Diego, CA, on November 4th, 2023. “We are very encouraged by two partial responses and three durable stable diseases in patients with advanced cancer who had progressed on multiple prior therapies, reinforcing MDNA11's promising single-agent activity,” said Fahar Merchant, Ph.D.

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics (NASDAQ: MDNA ) stock is falling on Monday after the immunotherapy company alerted investors to a delisting notice. Medicenna Therapeutics notes that it received the delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market.

Why Is Medicenna Therapeutics (MDNA) Stock Down Today?

The Company's listing on the Toronto Stock Exchange will not be impacted The Company's listing on the Toronto Stock Exchange will not be impacted

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) to be held in San Diego, CA, from November 1-5th, 2023.

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders held today, September 28, 2023 (the “Meeting”).

Medicenna Announces Results of Annual and Special Meeting of Shareholders

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 - 4, 2023, in Toronto, Canada.

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

TORONTO and HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the appointment of Brent Meadows, MBA, as its Chief Business Officer (“CBO”), as part of the Company's plans to establish a world-class C-suite in Boston, the industry's largest biotech hub. Mr. Meadows brings over 25 years of business development, commercial strategy and marketing experience at large pharma and biotech companies, including Johnson & Johnson, Bristol-Myers Squibb, Shire/Baxalta, and Regeneron, among others.

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11 - Immune pharmacodynamic data continues to support a differentiated mechanism with preferential expansion of potent cancer-fighting immune cells - The monotherapy Recommended Dose for Expansion was established at 90g/kg administered every 2 weeks TORONTO and HOUSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced a clinical update on the monotherapy dose escalation portion of the first-in-human, Phase 1/2 ABILITY Study in patients with advanced solid tumors, as its drug candidate MDNA11, a beta-only, long-acting IL-2 super-agonist, advances to the monotherapy dose expansion phase. “We are pleased to see that MDNA11 continues to demonstrate durable single-agent activity in patients with advanced, treatment-refractory cancer, together with a manageable safety profile, and preserving its differentiated pharmacodynamic (PD) qualities, even though the Phase 1 ABILITY Study was not specifically designed to demonstrate efficacy,” said Fahar Merchant, Ph.D.

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors.

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No. 11,680,090, titled "Interleukin-2 Fusion Proteins and Uses Thereof." The patent further strengthens Medicenna's intellectual property around its BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform.

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

TORONTO and HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced financial results and corporate highlights for the first quarter ended June 30, 2023, as well as anticipated near-term corporate milestones.

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

TORONTO and HOUSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, the Company's President and CEO, was invited to participate and present at the Research Roundtable organized by the National Brain Tumor Society (NBTS). The event, titled “Use of External Control Data in Brain Tumor Clinical Trials” took place on July 20, 2023, in Washington, D.C.

Medicenna Presents at National Brain Tumor Society's Research Round Table

TORONTO and HOUSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today reported financial results and corporate highlights for the fiscal year ended March 31, 2023, as well as anticipated near-term corporate milestones.

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on April 25, 2023 it received a notice (the “Extension Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company's request for a 180-day extension to regain compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1). The Company was first notified by Nasdaq of its failure to comply with the Minimum Bid Requirement on October 25, 2022, and was given until April 24, 2023 to regain compliance. The Company now has until October 23, 2023 to meet the requirement.

Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and management will participate in one-on-one meetings at the 2023 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 25-26, 2023.

Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

-- IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but minimally expressed in normal tissues

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023.

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference, which is scheduled to take place virtually from March 13 – 15, 2023.

Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference

Medicenna is testing MDNA11, an IL-2 superkine, with potential in various cancer types, in a phase 1/2 trial called ABILITY. A February 2023 update tells us MDNA stock has been able to increase the dose of MDNA11 without issues so far.

News for Medicenna Therapeutics Corp Stock (MDNA)